Akums Drugs & Pharma Stock Screener | Share Price & Fundamental Analysis
AKUMS
Pharmaceuticals
Screen Akums Drugs & Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹444.80
▼
-2.55 (-0.57%)
Share Price BSE
₹444.20
▼
-3.25 (-0.73%)
Market Cap
₹7,018.20 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
2.27
EPS (TTM)
₹22.60
Dividend Yield
-
Debt to Equity
0.17
52W High
₹632.70
52W Low
₹414.05
Operating Margin
9.00%
Profit Margin
4.10%
Revenue (TTM)
₹1,050.00
EBITDA
₹127.00
Net Income
₹43.00
Total Assets
₹4,113.00
Total Equity
₹3,064.00
Akums Drugs & Pharma Share Price History - Stock Screener Chart
Screen AKUMS historical share price movements with interactive charts. Analyze price trends and patterns.
Akums Drugs & Pharma Company Profile - Fundamental Screener
Screen Akums Drugs & Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AKUMS shares.
Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and development, regulatory dossier preparation and filing, and testing services. Akums has manufacturing units accredited by global regulatory agencies and specializes in various therapeutic areas. The company has expanded through acquisitions and establishment of new facilities over the years. It operates in three main segments: CDMO, API, and Branded and Generic formulations. Akums has manufactured over 4,000 commercialized formulations across more than 60 dosage forms.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE09XN01023
Website
https://www.akums.in
Akums Drugs & Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen AKUMS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 4,113 | 3,516 | 3,267 | 3,069 | 2,192 | 2,078 |
| Current Assets | 2,275 | 1,941 | 1,879 | 1,864 | 1,157 | 1,250 |
| Fixed Assets | 1,397 | 1,191 | 1,097 | 1,021 | 834 | 645 |
| Liabilities | ||||||
| Total Liabilities | 4,113 | 3,516 | 3,267 | 3,069 | 2,192 | 2,078 |
| Current Liabilities | 156 | 1,585 | 1,278 | 1,172 | 725 | 627 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 3,064 | 721 | 723 | 625 | 887 | 721 |
| Share Capital | 31 | 29 | 29 | 14 | 1 | 1 |
| Reserves & Surplus | 3,016 | 681 | 689 | 608 | 884 | 721 |
Screen AKUMS income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,050 | 1,051 | 1,081 | 1,030 | 1,050 | 1,026 | 955 | 1,093 | 1,188 | 978 |
| Expenses | 923 | 895 | 962 | 889 | 912 | 891 | 941 | 989 | 1,057 | 1,095 |
| EBITDA | 127 | 156 | 120 | 141 | 138 | 135 | 14 | 103 | 131 | -117 |
| Operating Profit % | 9.00% | 13.00% | 9.00% | 12.00% | 12.00% | 13.00% | 0.00% | 9.00% | 11.00% | -13.00% |
| Depreciation | 38 | 37 | 40 | 45 | 35 | 34 | 34 | 32 | 30 | 30 |
| Interest | 23 | 23 | 5 | 5 | 12 | 13 | 12 | 12 | 14 | 12 |
| Profit Before Tax | 66 | 96 | 75 | 91 | 92 | 88 | -33 | 59 | 87 | -159 |
| Tax | 23 | 31 | -75 | 25 | 25 | 26 | 7 | -136 | 54 | 29 |
| Net Profit | 43 | 65 | 150 | 66 | 67 | 61 | -40 | 195 | 33 | -187 |
| EPS | 2.66 | 4.15 | 9.64 | 4.26 | 4.37 | 4.21 | -2.89 | 13.21 | 2.22 | -13.16 |
Akums Drugs & Pharma Cash Flow Screener - Liquidity Fundamentals
Screen AKUMS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 465 | 498 | 177 | 32 | 135 | 28 | 89 | 72 |
| Investing Activities | -548 | -331 | -305 | -235 | -109 | -190 | -123 | -150 |
| Financing Activities | 73 | -108 | 125 | 236 | -95 | 233 | 37 | 66 |
| Net Cash Flow | -10 | 59 | -4 | 33 | -70 | 71 | 4 | -11 |
Screen AKUMS shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Aug | 2024-Feb |
|---|---|---|---|---|---|---|---|
| Promoter Holding | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 75.26% | 84.91% |
| FII Holding | 2.28% | 4.24% | 5.77% | 6.36% | 7.34% | 5.32% | 0.00% |
| DII Holding | 9.28% | 8.85% | 7.40% | 7.00% | 7.52% | 7.60% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 5.01% | 3.60% | 3.41% | 3.33% | 2.11% | 4.43% | 0.00% |
| Other Holding | 8.18% | 8.05% | 8.16% | 8.05% | 7.77% | 7.38% | 15.09% |
| Shareholder Count | 75,365 | 69,424 | 69,366 | 68,410 | 57,531 | 138,205 | 8 |
Akums Drugs & Pharma Dividend Screener - Share Yield Analysis
Screen AKUMS dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Akums Drugs & Pharma Index Membership - Market Screener Classification
Screen AKUMS by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Akums Drugs & Pharma Market Events Screener - Corporate Actions
Screen AKUMS market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -0.29% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | -4.50% |
| 2025-07-18 | 2025-07-18 | Annual General Meeting | NA | -1.09% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | 3.58% |
| 2025-02-06 | 2025-02-06 | Quarterly Result Announcement | NA | 0.66% |
| 2024-11-09 | 2024-11-09 | Quarterly Result Announcement | NA | -5.76% |
Akums Drugs & Pharma Competitors Screener - Peer Comparison
Screen AKUMS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,950 | 39.35 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,413 | 68.31 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,247 | 60.76 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,238 | 22.46 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,613 | 18.49 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,056 | 22.19 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,075 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 89,356 | 51.11 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 69,290 | 20.05 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,324 | 27.31 | 13,458 | 3.70% | 2,216 | 38.49 |
Akums Drugs & Pharma Company Announcements - News Screener
Screen AKUMS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-03 | Resignation Of Senior Management Personnel | View |
| 2026-01-03 | Closure of Trading Window | View |
| 2025-12-29 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-12-29 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-12-16 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update | View |
| 2025-12-15 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-12-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-13 | Update | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-13 | Outcome Of Board Meeting | View |
| 2025-11-13 | Board Meeting Outcome for Outcome Of Board Meeting | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-08 | Board Meeting Intimation for Consider And Approve The Un-Audited (Standalone & Consolidated) Financial Results For The Quarter And Half Year Ended On 30Th September 2025 | View |